Clinical trials: Molecular Targeted Therapies
Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents
A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935
The purpose of this study is to determine the brain cholesterol 24S-hydroxylase (CH24H) enzyme occupancy of TAK-935 after single oral dose in healthy participants using the positron emission tomography (PET) ligand [18F]MNI-792…
- Trial name
- NCT02497235
- Testing
- TAK-935, [18F]MNI-792 (tracer)
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Takeda
Advanced Non-small Cell Lung Cancer (NSCLC)
Impact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic Pathway
This multicenter pilot observational study aims to assess the feasibility of introducing liquid biopsy at an early stage of the diagnostic pathway for patients with suspected advanced non-small cell lung cancer (NSCLC).
- Trial name
- INNOVA-LUNG (NCT07649629)
- Testing
- Plasma-based liquid biopsy
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Regina Elena Cancer Institute
Renal Cell Carcinoma (Kidney Cancer), Immunotherapy
Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial
This phase II, multicenter, single-arm, open-label study evaluates first-line ipilimumab N01 plus sintilimab and lenvatinib in patients with locally advanced or metastatic TFE3-rearranged renal cell carcinoma (TFE3-rRCC), a rare…
- Conditions
- Renal Cell Carcinoma (Kidney Cancer), Immunotherapy, Molecular Targeted Therapy
- Trial name
- NCT07715565
- Testing
- Ipilimumab Injection, Sintilimab injection, Lenvatinib
- Where
- China
- Volunteers
- 66 people
- Sponsor
- West China Hospital
Squamous Cell Carcinoma of the Head and Neck
Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients
The investigators will collect plasma samples at baseline, during treatment, and at progression.
- Trial name
- NCT02139020
- Testing
- Plasma samples
- Where
- 5 sites in Belgium
- Volunteers
- 400 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Breast Cancer
Prognosis and Targeted Therapy Related Molecular Screening Program for Patients of Breast Cancer in China
The anticipated objectives of this study are: 1) to understand the pathogenesis and molecular typing of breast cancer patients in China (mainly HER2 overexpression, triple negative and hormone receptor-positive patients) by…
- Trial name
- NCT03792529
- Testing
- detect gene mutations of ctDNA and ctRNA
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University Cancer Hospital & Institute
Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2A
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
Background: Medullary thyroid carcinoma (MTC) is common in people with a genetic disorder called multiple endocrine neoplasia (MEN).
- Conditions
- Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2A, Multiple Endocrine Neoplasia Type 2B
- Trial name
- NCT00514046
- Testing
- Vandetanib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Malignant Melanoma
Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis
This multicenter, retrospective observational study aims to identify clinical, pathological, and molecular factors associated with prognosis and treatment response in patients with metastatic malignant melanoma.
- Trial name
- MEL-CARE (NCT07256184)
- Testing
- Systemic Therapy for Metastatic Melanoma
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 232 people
- Sponsor
- Ankara Etlik City Hospital
Haematological Malignancy, Melanoma
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma.
- Conditions
- Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms
- Trial name
- DETERMINE (NCT05768178)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 16 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Abdominal Aortic Aneurysm (AAA), No Abdominal Aortic Aneurysm (Non-AAA)
NIH CCR2 AAA Study
Abdominal aortic aneurysm (AAA) is a degenerative vascular disease, which is typically asymptomatic until rupture, resulting in high mortality.
- Trial name
- NCT04586452
- Testing
- AAA Group (Aim 3A), Non-AAA Group, Ex Vivo Human AAA Specimens (Aim 2A)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Washington University School of Medicine
Reccurent/Metastatic Solid Tumor Disease
A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer
SHIVA is a proof of concept randomized phase II trial which compares two treatment strategies for patients with refractory cancer.
- Trial name
- SHIVA (NCT01771458)
- Testing
- Targeted therapy based on molecular profiling : Imatinib, Tumor biopsy, Standard Chemotherapy
- Where
- 8 sites in France
- Volunteers
- 742 people
- Sponsor
- Institut Curie
Cancer, Non Small Cell Lung Cancer
Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients
This exploratory clinical study is designed to obtain pre-therapeutic imaging assessments using positron emission tomography (PET) imaging in 21 patients with Stage IIIB/IV or recurrent non-small cell lung cancer (NSCLC) and an…
- Trial name
- NCT00708448
- Testing
- PET Imaging, Erlotinib, Bevacizumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Utah
Metformin, Prediabetes
Metformin and Molecular Aging in Prediabetes
The incidence and prevalence of type 2 diabetes mellitus (T2DM) are increasing globally. The global prevalence of diabetes has nearly doubled since 1980, rising from 4.7% to 8.5% in the adult population.
- Trial name
- NCT07302932
- Testing
- Metformin treatment, Analyzed by qPCR for T/S ratio.
- Where
- India
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Diabetes Foundation, India
Metastatic Solid Tumors (Any Localization)
Molecular Screening for Cancer Treatment Optimization
The primary objective of the study is to use high throughput molecular analysis (CGH Array and sequencing) to treat patients with metastatic cancer with targeted therapeutics in order to improve the progression free survival…
- Trial name
- MOSCATO 02 (NCT01566019)
- Testing
- Tumoral biopsy
- Where
- France
- Volunteers
- 2,150 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Cancer;Cardiovascular;Adverse Events, Cancer
Multicenter Prospective Observational Study of Cardiotoxicity in Patients Receiving Targeted Cancer Therapies
This study will prospectively monitor cancer patients receiving chemotherapy (including molecular targeted therapies) for cardiovascular adverse events using biomarkers and imaging.
- Trial name
- NCT07058454
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Solid Tumour, Haematological Malignancy
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
This clinical trial is looking at a drug called capmatinib. Capmatinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Solid Tumour, Haematological Malignancy, Malignant Neoplasm, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT06988475)
- Testing
- Capmatinib
- Where
- 17 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Chondrosarcomas, Cartilage Tumours
Diagnostic and Therapeutic Targets in Cartilaginous Tumours
This study, "Finding new diagnostic and therapeutic targets in cartilaginous tumours," focuses on improving the diagnosis, prognostic stratification, and treatment options for chondroid tumours, particularly chondrosarcoma.
- Trial name
- NCT07315542
- Testing
- Tumour tissue analysis, Molecular validation, Liquid biopsy analysis
- Where
- Czechia
- Volunteers
- 300 people
- Sponsor
- St. Anne's University Hospital Brno, Czech Republic
Hepatocellular Carcinoma, Immunotherapy
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Hepatectomy is a curable and effective method. However, the recurrence rate is as high as 50%~70% in 5 years after surgery.
- Conditions
- Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy
- Trial name
- NCT04521153
- Testing
- Camrelizumab, Apatinib Mesylate, Radical surgery
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Shanghai Zhongshan Hospital
Tumor
Research on NI-FAPI-04 for the Treatment of Hypoxic and Fibroblast Activation Protein Related Tumors
Exploring the therapeutic value of a novel dual target molecular probe NI-FAPI-04 PET/CT with hypoxia and fibroblast activation related proteins in fibroblast activation related tumors.
- Trial name
- NCT07822347
- Testing
- Injection of 177Lu-NI-FAPI
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Solid Tumor
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
This was an open-label, Phase 1/2, dose escalation and signal finding study of derazantinib administered to patients with advanced solid tumors (Part 1; Dose Escalation/Food-effect Cohorts) or with advanced solid tumors with FGFR…
- Trial name
- NCT01752920
- Testing
- Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose range
- Where
- 12 sites in United States, Italy
- Volunteers
- 119 people
- Sponsor
- Basilea Pharmaceutica
Lung Neoplasms, Psychological Distress
Association of Psychological Distress in Patients With Lung Cancer
Psychological distress is a multi-factorial experience of a psychological, social, spiritual, and/or physical nature that may interfere with one's ability to cope effectively with cancer, physical symptoms and treatment.
- Conditions
- Lung Neoplasms, Psychological Distress, Prognosis Factors, Lifestyle, Healthy
- Trial name
- Life-Score (NCT06218901)
- Testing
- immunotherapy, Targeted Therapy Agent
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chest Hospital